Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

1.700 -0.070 (-3.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	464,541
Open	1.750
Bid (Size)	1.740 (600)
Ask (Size)	1.750 (3,600)
Prev. Close	1.770
Today's Range	1.690 - 1.760
52wk Range	1.580 - 3.840
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA

Today 11:45 EST

Via ACCESS Newswire

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

March 02, 2026

Via Investor Brand Network

Performance

YTD	-35.1%	-35.1%
1 Month	-7.6%	-7.6%
3 Month	-28.0%	-28.0%
6 Month	-38.2%	-38.2%
1 Year	-21.3%	-21.3%

More News

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

March 02, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Builds Momentum From FDA Progress To Strategic Expansion

February 27, 2026

Via NewMediaWire

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

NRx Builds Momentum From FDA Progress To Strategic Expansion

February 27, 2026

Via TheNewswire.com

FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

February 17, 2026

Via Get News

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway

February 17, 2026

Via Investor Brand Network

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

February 17, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

January 16, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

January 14, 2026

Via Get News

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

January 14, 2026

Via Investor Brand Network

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

January 14, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network

January 05, 2026

Via Investor Brand Network

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

January 05, 2026

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

December 18, 2025

Via Investor Brand Network

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

December 18, 2025

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

December 03, 2025

Via Get News

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

December 03, 2025

Via Investor Brand Network

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

December 03, 2025

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

December 02, 2025

Via Get News

InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

December 02, 2025

Via Investor Brand Network

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2

December 02, 2025

Via Investor Brand Network

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

December 02, 2025

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

December 02, 2025

From NRx Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?

NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market

What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?

The current price of NRX Pharmaceuticals, Inc. - Common Stock is 1.700

When was NRX Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 03/06/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.